Middle East And Africa Igg4 Related Disease Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2021 –2028 |
 Tamaño del mercado (año base) |
USD 83.72 Million |
 Tamaño del mercado (año de pronóstico) |
USD 97.82 Million |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
>Mercado de enfermedades relacionadas con IgG4 en Oriente Medio y África, por tipo de enfermedad (pancreatitis autoinmune (AIP) de tipo 1 (relacionada con IgG4), fibrosis retroperitoneal, nefritis tubulointersticial (TIN) relacionada con IgG4, colangitis esclerosante relacionada con IgG4, dacrioadenitis y sialadenitis relacionadas con IgG4, paquimeningitis relacionada con IgG4, enfermedad tiroidea relacionada con IgG4 , concentración sérica de IgG4 y otras), tipo (diagnóstico y tratamiento), vía de administración (parenteral, oral y otras), usuario final (hospitales, clínicas especializadas y otras), canal de distribución (farmacia hospitalaria, farmacia minorista , farmacia en línea y otras), país (Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Egipto, Kuwait, Israel, resto de Oriente Medio y África). Tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado: mercado de enfermedades relacionadas con IgG4 en Oriente Medio y África
Se espera que el mercado de enfermedades relacionadas con IgG4 de Oriente Medio y África gane un crecimiento significativo entre 2021 y 2028. Data Bridge Market Research analiza que el mercado de enfermedades relacionadas con IgG4 de Oriente Medio y África está creciendo con una CAGR del 2,3% en el período de pronóstico de 2021 a 2028 y se espera que alcance los 97,82 millones de dólares en 2028 desde los 83,72 millones de dólares en 2020. El aumento del gasto sanitario y una cantidad apreciable de corticoides y fabricantes de medicamentos genéricos son los principales impulsores que se espera que impulsen el crecimiento del mercado en el período de pronóstico.
Cada vez hay más personas afectadas por enfermedades relacionadas con la IgG4, que exigen un tratamiento avanzado y altamente eficaz para minimizar el riesgo. Los sistemas sanitarios necesitan medicamentos muy avanzados para numerosos tipos diferentes de enfermedades relacionadas con la IgG4 durante el tratamiento de los pacientes. Por lo tanto, los principales actores del mercado se centran en gran medida en los lanzamientos y las aprobaciones de productos. Además, el gobierno y los organismos reguladores están apoyando a los actores del mercado en la aprobación de productos.
La creciente concienciación sobre las enfermedades relacionadas con la IgG4 entre la población puede actuar como un motor para el mercado de enfermedades relacionadas con la IgG4 en Oriente Medio y África. Por otro lado, el alto coste del tratamiento puede reorientar el mercado. Las iniciativas estratégicas de los agentes del mercado plantean una oportunidad para el crecimiento del mercado. Se espera que la falta de profesionales cualificados suponga un reto para el mercado de enfermedades relacionadas con la IgG4 en Oriente Medio y África.
El informe de mercado de enfermedades relacionadas con IgG4 en Oriente Medio y África proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsas de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un resumen de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Middle East and Africa IgG4-Related Disease Market Scope and Market Size
The Middle East and Africa IgG4-related disease market is segmented based on disease type, type, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the Middle East and Africa IgG4-related disease market is segmented into type 1 (IgG4-related) autoimmune pancreatitis (AIP), retroperitoneal fibrosis, IgG4-related tubulointerstitial nephritis (TIN), igg4-related sclerosing cholangitis IgG4-related dacryoadenitis and sialadenitis, IgG4-related pachymeningitis, IgG4-related thyroid disease, serum IgG4 concentration, and others. In 2021, the IgG4-related dacryoadenitis and sialadenitis segment is expected to dominate the market due to rising awareness among the target population.
- On the basis of type, the Middle East and Africa IgG4-related disease market is segmented into diagnostic and treatment. In 2021, the diagnostics segment is expected to dominate the market because of increasing healthcare expenditure.
- On the basis of route of administration, the Middle East and Africa IgG4-related disease market is segmented into oral, parenteral, and others. In 2021, the parenteral segment is expected to dominate the market because it is the most effective mode of administration.
- On the basis of end-user, the Middle East and Africa IgG4-related disease market is segmented into hospitals, specialty clinics, others. In 2021, the hospital's segment is expected to dominate the market because of rising government funds.
- On the basis of distribution channel, the Middle East and Africa IgG4-related disease market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2021, the hospital pharmacy segment is expected to dominate the market owing to the rising product launches by key market players.
Middle East and Africa IgG4-Related Disease Market Country Level Analysis
The Middle East and Africa IgG4-related disease market is analyzed, and market size information is provided based on disease type, type, route of administration, end-user, and distribution channel. The countries covered in the Middle East and Africa IgG4-related disease market are Saudi Arabia, South Africa, UAE, Egypt, Kuwait, Israel, the Rest of the Middle East, and Africa.
Saudi Arabia is expected to dominate the Middle East and Africa IgG4-related disease market due to increasing rising government funding in the region.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of the Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Rising healthcare expenditure and escalation in innovations and technologies in the Middle East and Africa igG4-related disease market are creating new opportunities for players
IgG4-related disease by disease type segment in Saudi Arabia is expected to grow with the highest rate. It is dominating the region in the forecast period of 2021 to 2028 because of rising government funding.
The Middle East and Africa IgG4-related disease market also provides you with detailed market analysis for every country's growth in a particular industry with the market sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the Middle East and Africa IgG4-related disease market. The data is available for the historical period 2010 to 2019.
Competitive Landscape and the Middle East and Africa IgG4-Related Disease Market Share Analysis
The Middle East and Africa IgG4-related disease market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, and technology lifeline curve. The above data points are only related to the companies’ focus on the Middle East and Africa IgG4-related disease market.
Major players covered in the Middle East and Africa IgG4-related disease report are Zydus Cadila, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd, Baxter, Viatris Inc., Amgen Inc., Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA), Pfizer Inc., Cipla Inc., Accord-UK Ltd., among others domestic and the Middle East and Africa players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launches and agreements are also initiated by the companies worldwide, further accelerating the Middle East and Africa IgG4-related disease market.
For instance,
- En enero de 2020, Amgen Inc. anunció una colaboración estratégica exitosa con BeiGene. Se prevé que esta colaboración mejore la presencia de la empresa en el mercado de oncología de China en los próximos años.
- En noviembre de 2020, Accord Healthcare anunció que era la empresa más reconocida en los premios Global Generics & Biosimilar Awards 2020, al haber ganado el premio a la Empresa del Año, el Logro Regulatorio del Año y la Iniciativa de Responsabilidad Corporativa del Año. Esto ha aumentado las ventas y la demanda del producto y ayuda a generar ingresos.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
5 REGIONAL SUMMARY
5.1 SUMMARY WRITE UP (NORTH AMERICA)
5.1.1 OVERVIEW
5.2 SUMMARY WRITE UP (EUROPE)
5.2.1 OVERVIEW
5.3 SUMMARY WRITE UP (ASIA-PACIFIC)
5.3.1 OVERVIEW
5.4 SUMMARY WRITE UP (SOUTH AMERICA)
5.4.1 OVERVIEW
5.5 SUMMARY WRITE UP (MIDDLE EAST AND AFRICA)
5.5.1 OVERVIEW
6 EPIDEMIOLOGY
7 REGULATORY GUIDELINES FOR MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET
7.1 U.S. REGULATORY FRAMEWORK
7.2 EUROPE REGULATORY FRAMEWORK
7.3 JAPAN REGULATORY FRAMEWORK
8 PIPELINE ANALYSIS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISING AWARENESS ABOUT IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD)
9.1.2 ESCALATION IN INNOVATION AND TECHNOLOGIES
9.1.3 INCREASE IN RESEARCH & DEVELOPMENT INVESTMENT FOR DRUG DISCOVERY
9.2 RESTRAINTS
9.2.1 HIGH COST OF IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD) TREATMENT
9.2.2 ADVERSE EFFECTS ASSOCIATED WITH TREATMENT
9.3 OPPORTUNITIES
9.3.1 RISING EXPENDITURE ON HEALTHCARE
9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
9.3.3 GOVERNMENT FUNDING FOR RESEARCH PURPOSE
9.4 CHALLENGE
9.4.1 DIFFICULT DIAGNOSIS AND MANGEMENT OF THE DISEASE
10 IMPACT OF COVID 19 PANDEMIC ON THE MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON SUPPLY CHAIN
10.3 IMPACT ON DEMAND
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE
11.1 OVERVIEW
11.2 IGG4-RELATED DACRYOADENITIS AND SIALADENITIS
11.3 RETROPERITONEAL FIBROSIS
11.4 IGG4-RELATED THYROID DISEASE
11.5 IGG4-RELATED TUBULOINTERSTITIAL NEPHRITIS (TIN)
11.6 IGG4-RELATED SCLEROSING CHOLANGITIS
11.7 TYPE 1 (IGG4-RELATED) AUTOIMMUNE PANCREATITIS (AIP)
11.8 IGG4-RELATED PACHYMENINGITIS
11.9 OTHERS
12 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY TYPE
12.1 OVERVIEW
12.2 DIAGNOSTIC
12.2.1 IMAGING
12.2.1.1 COMPUTED TOMOGRAPHY (CT)
12.2.1.2 MAGNETIC RESONANCE IMAGING (MRI)
12.2.1.3 PET/CT
12.2.1.4 OTHERS
12.2.2 LABORATORY TESTING (SERUM IGG4 CONCENTRATION)
12.2.3 FLOW CYTOMETRY
12.2.4 OTHERS
12.3 TREATMENT
12.3.1 RITUXIMAB
12.3.2 CYCLOPHOSPHAMIDE
12.3.3 METHOTREXATE
12.3.4 STEROIDS
12.3.4.1 Methylprednisolone
12.3.4.2 Prednisolone
12.3.4.3 others
12.3.5 AZATHIOPRINE
12.3.6 OTHERS
13 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 PARENTERAL
13.3 ORAL
13.4 OTHERS
14 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 OTHERS
15 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE PHARMACY
15.5 OTHERS
16 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY REGION
16.1 MIDDLE EAST AND AFRICA
16.1.1 SAUDI ARABIA
16.1.2 SOUTH AFRICA
16.1.3 UAE
16.1.4 EGYPT
16.1.5 ISRAEL
16.1.6 KUWAIT
16.1.7 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 PFIZER INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 AMGEN INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 GENENTECH, INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 COMPANY SHARE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 CELLTRION HEALTHCARE CO., LTD.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 ACCORD-UK LTD.
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 AMNEAL PHARMACEUTICALS LLC
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 ANI PHARMACEUTICALS, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 ANTARES PHARMA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 BAXTER
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 CIPLA INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 HIKMA PHARMACEUTICALS PLC
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 INGENUS PHARMACEUTICALS
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 LANNETT
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 SEBELA PHARMACEUTICALS
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 STI PHARMA
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 VIATRIS INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
19.2 ZYDUS CADILA
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
20 COMPANIES WITH PRODUCTS IN PHASE II AND PHASE III CLINICAL TRIALS
20.1 SANOFI
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENT
20.2 XENCOR
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENT
20.3 BRISTOL-MYERS SQUIBB COMPANY
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 HORIZON THERAPEUTICS PLC
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Lista de Tablas
TABLE 1 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, PIPELINE ANALYSIS
TABLE 2 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA IGG4-RELATED DACRYOADENITIS AND SIALADENITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA RETROPERITONEAL FIBROSIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA IGG4-RELATED THYROID DISEASE IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA IGG4-RELATED TUBULOINTERSTITIAL NEPHRITIS (TIN) IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA IGG4-RELATED SCLEROSING CHOLANGITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA TYPE 1 (IGG4-RELATED) AUTOIMMUNE PANCREATITIS (AIP) IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA IGG4-RELATED PACHYMENINGITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA PARENTERAL IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA ORAL IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY END USERS, 2019-2028 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA HOSPITALS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 41 SAUDI ARABIA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 42 SAUDI ARABIA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 43 SAUDI ARABIA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 44 SAUDI ARABIA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 45 SAUDI ARABIA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 46 SAUDI ARABIA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 47 SAUDI ARABIA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 48 SAUDI ARABIA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 49 SAUDI ARABIA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 50 SOUTH AFRICA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 51 SOUTH AFRICA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 52 SOUTH AFRICA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 53 SOUTH AFRICA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 54 SOUTH AFRICA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 55 SOUTH AFRICA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 56 SOUTH AFRICA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 57 SOUTH AFRICA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 58 SOUTH AFRICA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 59 UAE IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 60 UAE IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 61 UAE DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 62 UAE IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 63 UAE TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 64 UAE STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 65 UAE IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 66 UAE IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 67 UAE IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 68 EGYPT IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 69 EGYPT IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 70 EGYPT DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 71 EGYPT IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 72 EGYPT TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 73 EGYPT STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 74 EGYPT IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 75 EGYPT IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 76 EGYPT IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 77 ISRAEL IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 78 ISRAEL IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 79 ISRAEL DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 80 ISRAEL IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 81 ISRAEL TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 82 ISRAEL STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 83 ISRAEL IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 84 ISRAEL IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 85 ISRAEL IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 86 KUWAIT IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 87 KUWAIT IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 88 KUWAIT DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 89 KUWAIT IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 90 KUWAIT TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 91 KUWAIT STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 92 KUWAIT IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 93 KUWAIT IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 94 KUWAIT IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 95 REST OF MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
Lista de figuras
FIGURE 1 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET : SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET : DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET : DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET : SEGMENTATION
FIGURE 11 INCREASING AWARENESS FOR IGG4-RELATED DISEASES AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 IGG4-RELATED DACRYOADENITIS AND SIALADENITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET
FIGURE 14 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, 2020
FIGURE 15 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
FIGURE 16 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 17 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY TYPE, 2020
FIGURE 19 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY TYPE, 2019-2028 (USD THOUSAND)
FIGURE 20 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 21 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 23 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
FIGURE 24 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 25 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY END USERS, 2020
FIGURE 27 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY END USERS, 2019-2028 (USD THOUSAND)
FIGURE 28 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 29 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY END USERS, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 31 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
FIGURE 32 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL,CAGR (2021-2028)
FIGURE 33 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: SNAPSHOT (2020)
FIGURE 35 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY COUNTRY (2020)
FIGURE 36 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY COUNTRY (2021 & 2028)
FIGURE 37 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY COUNTRY (2020 & 2028)
FIGURE 38 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 39 MIDDLE EAST AND AFRICA IGG4-RELATED DISEASEMARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
